DDInter909 DDInter1266
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Naproxen
Imatinib {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Naproxen
Imatinib {u} (Compound) causes {v} (Side Effect) Muscular weakness
Muscular weakness {u} (Side Effect) is caused by {v} (Compound) Naproxen
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Ibuprofen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Indomethacin
Indomethacin {u} (Compound) resembles {v} (Compound) Agomelatine
Agomelatine {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Nabumetone
Nabumetone {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib {u} (Compound) causes {v} (Side Effect) Muscular weakness
Muscular weakness {u} (Side Effect) is caused by {v} (Compound) Flurbiprofen
Flurbiprofen {u} (Compound) resembles {v} (Compound) Naproxen
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Naproxen (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Naproxen (Compound)
Imatinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Naproxen (Compound)
Imatinib (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Naproxen (Compound)
Imatinib (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Naproxen (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Agomelatine (Compound) and Agomelatine (Compound) resembles Naproxen (Compound)
Imatinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Suprofen (Compound) and Suprofen (Compound) resembles Naproxen (Compound)
Imatinib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nabumetone (Compound) and Nabumetone (Compound) resembles Naproxen (Compound)
Imatinib (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Flurbiprofen (Compound) and Flurbiprofen (Compound) resembles Naproxen (Compound)